Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

(RTTNews) - Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel disease, on Monday announced the appointment of Norman ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology firm engaged in the development of treatments for inflammatory bowel disease and other conditions, announced the appointment of ...

Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel ...

Norm has also worked on several recent M&A deals in the biotech industry. “We are excited to welcome Norm to the Organovo team,” said Keith Murphy, Executive Chairman. “With his extensive experience, ...

Organovo Holdings, Inc., a clinical stage biotechnology company focused on treating inflammatory bowel disease (IBD), has appointed Norman Staskey as the new Chief Financial Officer. Staskey ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease ...

Shares of NASDAQ:ONVO opened at $0.49 on Monday. Organovo has a 52-week low of $0.32 and a 52-week high of $1.74. The stock has a market cap of $7.48 million, a price-to-earnings ratio of -0.46 ...

SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology firm engaged in the development of treatments for inflammatory bowel disease and other conditions, announced the appointment of ...